Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 56.01% is in line with its 5-year average of 52.35%, near the high end of its 5-year range (34.31%–57.67%).
1.45% above its 12-month average of 55.21%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 56.87%.
GROSS MARGIN
56.01%
GROSS MARGIN AVG TTM
55.21%
GROSS MARGIN AVG 3Y
52.51%
GROSS MARGIN AVG 5Y
52.35%
GROSS MARGIN AVG 10Y
50.90%
GROSS MARGIN AVG 15Y
44.94%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.45%
CURRENT VS 3Y AVG
+6.66%
CURRENT VS 5Y AVG
+6.99%
CURRENT VS 10Y AVG
+10.04%
CURRENT VS 15Y AVG
+24.63%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+35.36%
vs the sector median at left
Tandem Diabetes Care, Inc.
Market Cap
$1.10B
Gross Margin
56.01%
TTM Avg
55.21%
3Y Avg
52.51%
5Y Avg
52.35%
Market Cap
$1.10B
Gross Margin
76.23%
TTM Avg
76.19%
3Y Avg
76.96%
5Y Avg
77.39%
Market Cap
$1.09B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.08B
Gross Margin
75.86%
TTM Avg
76.84%
3Y Avg
76.91%
5Y Avg
76.44%
Market Cap
$1.12B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.07B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.13B
Gross Margin
47.68%
TTM Avg
50.27%
3Y Avg
51.23%
5Y Avg
48.58%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tandem Diabetes Care, Inc. (TNDM) | $1.10B | 56.01% | 55.21% | 52.51% | 52.35% |
| STAAR Surgical Company (STAA)vs › | $1.10B | 76.23% | 76.19% | 76.96% | 77.39% |
| OPKO Health, Inc. (OPK)vs › | $1.10B | 21.10% | 32.36% | 32.56% | 33.45% |
| Replimune Group, Inc. (REPL)vs › | $1.10B | 0.00% | 0.00% | 0.00% | 0.00% |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.09B | 0.00% | 0.00% | 0.00% | 0.00% |
| IRadimed Corporation (IRMD)vs › | $1.08B | 75.86% | 76.84% | 76.91% | 76.44% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.12B | 0.00% | 0.00% | 0.00% | 0.00% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.07B | 0.00% | 0.00% | 0.00% | 0.00% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 47.68% | 50.27% | 51.23% | 48.58% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 73.28% | 75.19% | 72.82% | 72.76% |
Gross Margin
56.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 56.87% |
| 2026-03-31 | 55.33% |
| 2025-12-31 | 57.67% |
| 2025-09-30 | 53.88% |
| 2025-06-30 | 52.29% |
| 2025-03-31 | 50.51% |
| 2024-12-31 | 55.71% |
| 2024-09-30 | 34.31% |
| 2024-06-30 | 50.83% |
| 2024-03-31 | 49.39% |
| 2023-12-31 | 47.41% |
| 2023-09-30 | 48.35% |
| 2023-06-30 | 51.93% |
| 2023-03-31 | 48.95% |
| 2022-12-31 | 52.39% |
| 2022-09-30 | 51.05% |
| 2022-06-30 | 50.91% |
| 2022-03-31 | 51.78% |
| 2021-12-31 | 54.16% |
| 2021-09-30 | 53.86% |
| 2021-06-30 | 53.71% |
| 2021-03-31 | 51.96% |
| 2020-12-31 | 53.88% |
| 2020-09-30 | 52.84% |
| 2020-06-30 | 49.79% |
| 2020-03-31 | 51.33% |
| 2019-12-31 | 55.60% |
| 2019-09-30 | 53.54% |
| 2019-06-30 | 53.51% |
| 2019-03-31 | 50.54% |
| 2018-12-31 | 54.51% |
| 2018-09-30 | 47.11% |
| 2018-06-30 | 44.21% |
| 2018-03-31 | 41.81% |
| 2017-12-31 | 43.35% |
| 2017-09-30 | 43.97% |
| 2017-06-30 | 37.52% |
| 2017-03-31 | 35.59% |
| 2016-12-31 | 34.81% |
| 2016-09-30 | -12.83% |
| 2016-06-30 | 35.57% |
| 2016-03-31 | 34.54% |
| 2015-12-31 | 46.22% |
| 2015-09-30 | 35.08% |
| 2015-06-30 | 30.57% |
| 2015-03-31 | 22.81% |
| 2014-12-31 | 36.54% |
| 2014-09-30 | 32.54% |
| 2014-06-30 | 33.63% |
| 2014-03-31 | 10.75% |
| 2013-12-31 | 11.59% |
| 2013-09-30 | 32.57% |
| 2013-06-30 | 7.34% |
| 2013-03-31 | 37.38% |
| 2012-12-31 | -19.83% |
| 2012-09-30 | -413.72% |
